Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
about
Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-betTReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesteroneNeoadjuvant endocrine therapy in breast cancer: current role and future perspectivesSteroid hormones, steroid receptors, and breast cancer stem cellsForm and function: how estrogen and progesterone regulate the mammary epithelial hierarchyMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerProgesterone receptor modulates ERα action in breast cancer.RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast CancerFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyUsing large-scale molecular data sets to improve breast cancer treatment.Progesterone-targeted magnetic resonance imaging probesNuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signalingHormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyComparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer.Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer.Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnoverTrefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-upLong-range transcriptional control of progesterone receptor gene expressionMicroRNA regulation of progesterone receptor in breast cancerNovel Strategies to Improve the Endocrine Therapy of Breast Cancer.EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancerSubcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implicationsNuclear IRS-1 predicts tamoxifen response in patients with early breast cancer.Progesterone receptor action: defining a role in breast cancerProteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics.microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breastConcordance in histological and biological parameters between first and second primary breast cancers.FOXA1 as a therapeutic target for breast cancer.Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.Stratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.Lobular carcinoma of the breast with gastrointestinal metastasis.Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
P2860
Q24645449-3C5F4AC7-2A2F-4A27-8523-B3D88BAE4B8AQ24671974-F59B4665-25D6-4A04-BBD1-4E247223A691Q26773012-89C7F496-AEBF-4879-B3E7-1E93824CA6FEQ26799113-F23E081E-5C4A-41D5-A3D7-535436D85880Q26799290-04ADC1F3-6132-4AFB-8449-236A3983F65EQ27001260-05DB700C-7B1E-4A3D-8822-E886CFF1C0D8Q27316268-8213B729-DEC9-422C-9CF7-ABF69FB54042Q27670969-98007FF8-FFB2-47B9-B611-F472C7922841Q27851554-C15F37AE-F657-4DFE-A443-2CA0592389FAQ28084982-BFA3B711-137B-44F9-B9EA-4666D594D4E7Q28269080-21D8C78B-B70F-4B61-A490-082DC797EB5AQ30656126-12FB3D1A-C78B-4FB8-BAE6-DC9705113320Q30836342-BFDE76BC-FB80-4F4F-8D25-E1F736C6BDEAQ30908486-E6C742ED-5387-4166-893D-79651EBC05B0Q31031200-68E32EBC-731B-4E78-B369-DB6A2A0FB12CQ31132241-12EA946E-1CFD-49FF-8F7D-F9AF654883F5Q33551425-A9EC0546-026C-41DB-AA7D-13C90279226DQ33574310-6EB095D6-AD9D-4D02-A0CA-23FCF6A34C11Q33588369-E69EE708-4BF6-443F-8479-2752DC57BBA7Q33611408-CC80A0B0-9732-41FC-B77F-75F7EA3F2E44Q33628415-2A975BDE-A982-492C-9C84-B955473ED86DQ33634238-AF320ED9-7811-4A66-BAC3-2B4E55B61A24Q33688484-FCEEED57-44AF-433F-B9AC-7F2B20908459Q33727284-5F56FCBB-9118-41EB-A771-321E94AB3B12Q33793142-6AA26C1C-2083-48CB-892C-65824630AA53Q33801131-220574D7-CE38-4280-9E81-C1E831FDA7FCQ33816285-C7A9691A-5B58-49DD-9402-7EF29B465F9DQ33939890-0FBC9EEB-B890-45A5-8A6E-A0437FAA8002Q33998721-93A8C85F-DB0B-4FD5-91C5-02537626BA79Q34048140-2E6F5F1E-82BB-4ECB-8404-BE2E7C909359Q34109691-F71738EB-8B82-43CF-9ADC-7E07F6A3D2DFQ34230233-67E86DA2-4B8F-4E6A-91C1-31A283B9894DQ34374980-24D6A306-2E84-4451-9B93-916FADB9AABEQ34392800-0C6BE7D5-BCFD-44D8-98F8-8AC5C224BC7EQ34500780-431E94A7-5C1B-4DF2-AB74-EBF738861795Q34610510-C22ACCDE-8C0A-4C9F-8A28-C3C210C4076EQ34660130-8FC95F56-260B-4E66-A054-704FF80186A9Q34680457-DB63E84C-447C-4A21-A644-D0BC8E126655Q34689083-49E96142-9387-446C-B616-4F9FA20F7AC6Q34783850-36A24E17-FDD6-443C-AE43-F41659D83863
P2860
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Biology of progesterone recept ...... cations for endocrine therapy.
@ast
Biology of progesterone recept ...... cations for endocrine therapy.
@en
type
label
Biology of progesterone recept ...... cations for endocrine therapy.
@ast
Biology of progesterone recept ...... cations for endocrine therapy.
@en
prefLabel
Biology of progesterone recept ...... cations for endocrine therapy.
@ast
Biology of progesterone recept ...... cations for endocrine therapy.
@en
P2093
P356
P1476
Biology of progesterone recept ...... cations for endocrine therapy.
@en
P2093
Adrian V Lee
C Kent Osborne
Grazia Arpino
Rachel Schiff
Xiaojiang Cui
P304
P356
10.1200/JCO.2005.09.004
P407
P577
2005-10-01T00:00:00Z